Article thumbnail

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus

By Soon Ae Kim, Woo Ho Shim, Eun Hae Lee, Young Mi Lee, Sun Hee Beom, Eun Sook Kim, Jeong Seon Yoo, Ji Sun Nam, Min Ho Cho, Jong Suk Park, Chul Woo Ahn and Kyung Rae Kim
Topics: Original Article
Publisher: Korean Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:3122893
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: The Committee of the Korean Diabetes Association on the Epidemiology of Diabetes Mellitus.
  2. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
  3. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
  4. (2011). http://e-dmj.org the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care
  5. (2009). Impact of sitagliptin on markers of beta-cell function: a meta-analysis.
  6. (2005). Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab
  7. Incretin-based combination therapy in type 2 diabetes mellitus.
  8. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet
  9. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
  10. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence.
  11. Putting insulin glargine and malignancies into perspective.
  12. Quantification of the pancreatic beta-cell mass in normal and type 2 diabetic subjects in Korea.
  13. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
  14. Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
  15. Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
  16. Staged diabetes management according to individual patient insulin resistance and beta-cell function ameliorates glycaemic control in type 2 diabetes mellitus. Clin Endocrinol (Oxf)
  17. The combination of fasting plasma glucose and glycosylated hemoglobin as a predictor for type 2 diabetes in Korean adults.
  18. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.
  19. (1993). The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus.